tuneTypical Dose
5-15 g/day
Fiber Supplement
Dietary fiber
tuneTypical Dose
5-15 g/day
watchEffect Window
Days-to-weeks for bowel effects, weeks for cardiometabolic effects.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Fiber reliably supports bowel regularity and can improve LDL cholesterol when dosed consistently
The strongest evidence supports viscous fibers such as psyllium for constipation and LDL lowering, with modest additional glycemic and blood-pressure support in selected groups. Start low, increase gradually, and pair with hydration to reduce gas and bloating.
Increases stool bulk and viscosity, modulates glucose/cholesterol absorption, and supports SCFA generation.
Outcomes
Safety
Evidence
Jovanovski E, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018;108(5):922-932. doi:10.1093/ajcn/nqy115. PMID:30239559.
Population: Adults across lipid/cardiometabolic risk strata.
Dose protocol: Psyllium and related viscous fibers, mostly 4-12 weeks.
Key findings: Significant LDL reduction.
Notes: Some heterogeneity by dose/form and background diet.
Significant LDL reduction.
de Vries J, et al. Effects of beta-Fructans Fiber on Bowel Function: A Systematic Review and Meta-Analysis. Nutrients. 2019;11(1):91. doi:10.3390/nu11010091. PMID:30621208.
Population: Healthy and symptomatic cohorts.
Dose protocol: Beta-fructans across multiple doses and durations.
Key findings: Improvement in bowel movement frequency and stool outcomes.
Notes: Heterogeneity in chain length and study design.
Improvement in bowel movement frequency and stool outcomes.
Gibb RD, et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr. 2015;102(6):1604-1614. doi:10.3945/ajcn.115.106989. PMID:26561625.
Population: Euglycemia to treated type 2 diabetes populations.
Dose protocol: Psyllium supplementation protocols.
Key findings: Modest glycemic improvement, larger in poorer baseline control.
Notes: Mixed baseline control and concurrent therapy differences.
Modest glycemic improvement, larger in poorer baseline control.
Clark CCT, et al. The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med. 2020;35(6):1385-1399. doi:10.3904/kjim.2019.049. PMID:32066221.
Population: Adults with varied cardiometabolic profiles.
Dose protocol: Psyllium over several weeks.
Key findings: Small but significant BP lowering.
Notes: Moderate heterogeneity.
Small but significant BP lowering.
Noureddin S, et al. Effects of psyllium vs placebo on constipation, weight, glycemia, and lipids in type 2 diabetes with chronic constipation. Complement Ther Med. 2018;40:1-7. doi:10.1016/j.ctim.2018.07.004. PMID:30219432.
Population: Adults with type 2 diabetes and chronic constipation.
Dose protocol: Psyllium intervention vs placebo.
Key findings: Improved constipation with supportive cardiometabolic directionality.
Notes: Single-population trial limits generalizability.
Improved constipation with supportive cardiometabolic directionality.